DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 1 Eli Lilly's donanemab - 1 Eisai - 1 Eli Lilly's - 1 Sarah Dolan - 1 Dolan - 1 Mark Mintun - 1 donanameb - 1
Top related locs:
Indianapolis , Indiana U.S Biogen Black
Top related orgs:
Food and Drug Administration - 1 FDA - 1

Search resuls for: "donanameb"


2 mentions found


☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
  + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.
Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black
☆ Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
  + stars: | 2022-10-26 | by ( Tanaya Macheel | ) www.cnbc.com   time to read: +2 min
Biogen shares have a lot more potential upside for investors thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday. The upgrade followed the company's earnings call, which had a big focus on the drug, lecanemab, an anti-amyloid antibody that is in phase 3 trials. Goldman also raised its revenue estimates for the drug to $14 billion in 2035, compared with prior estimates of $2 billion. "The company is now poised to address the early Alzheimer's disease market in 2023+ following the recent topline lecanemab Ph3 (CLARITY-AD) data," Goldman analyst Salveen Richter said in a note. "With BIIB shares now trading at ~$270 post the topline CLARITY-AD data, there is roughly ~$80/share reflected in the stock for Alzhiemer's disease," Richter said.
0 next >>
Total: 2